HIV-resistance to viral entry inhibitors

Current Pharmaceutical Design

Volumn 10, Issue 15, 2004, Pages 1845-1860

  Menéndez Arias, Luis ^a   Esté, José A ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Antiviral; Entry; Fusion; Inhibition; Resistance

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOOROMETHYL)PHENYL]ETHYL]PIPERAZINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMD 070; AMD 2763; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CYCLAM DERIVATIVE; DEXTRAN SULFATE; E 913; ENFUVIRTIDE; HYBRID PROTEIN; INTEGRASE; KRH 1636; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PIPERAZINE DERIVATIVE; POLYANION; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; ZINTEVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CELL VIABILITY; CLINICAL STUDY; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PLASTICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; VIREMIA; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS VIRULENCE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 2442446904     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384574     Document Type: Review

References (157)

1. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
2. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354: 729-733.
3. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy. Nat Med 1999; 5: 512-517.
4. Moore JP, Stevenson M. New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000; 1: 40-49.
5. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312: 767-768.
6. Landau NR, Warton M, Littman DR. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Nature 1988; 334: 159-162.
7. Dumonceaux J, Nisole S, Chanel C, Quivet L, Amara A, Baleux F, et al. Spontaneous mutations in the env gene of the uman immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 1998; 72: 512-519.
8. Valente ST, Chanel C, Dumonceaux J, Olivier R, Marullo S, Briand P, et al. CXCR4 is down-regulated in cells infected with the CD4-independent X4 human immunodeficiency virus type 1 isolate m7NDK. J Virol 2001; 75: 439-447.
9. Saha K, Zhang J, Gupta A, Dave R, Yimen M, Zerhouni B. Isolation of primary HIV-1 that target CD8+ T lymphocytes using CD8 as a receptor. Nat Med 2001; 7: 65-72.
10. Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV the retrovirus of AIDS. Cell 1986; 45: 637-648.
11. Smith TF, Srinivasan A, Schochetman G, Marcus M, Myers G. The phylogenetic history of immunodeficiency viruses. Nature 1988; 333: 573-575.
12. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990; 265: 10373-10382.
13. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990; 249: 932-935.
14. Vasil S, Thakallapally R, Korber B, Foley B. Human Retroviruses and AIDS Database Theoretical Biology Los Alamos National Laboratories Los Alamos NM USA, 1998.
15. Freed EO, Myers DJ. Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 1992; 66: 5472-5478.
16. Page KA, Stearns SM, Littman DR. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J Virol 1992; 66: 524-533.
17. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. Conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998; 280: 1949-1953.
18. Wang WK, Dudek T, Essex M, Lee TH. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci USA 1999; 96: 4558-4562.
19. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989; 86: 6768-6772.
20. Skinner MA, Langlois AJ, McDanal CB, McDougal JS, Bolognesi DP, Matthews TJ. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol 1988; 62: 4195-4200.
21. Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, Rosen CA, et al. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 1985; 228: 1091-1094.
22. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-659.
23. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000; 74: 1961-1972.
24. Binley JM, Wyatt R, Desjardins E, Kwong PD, Hendrickson W, Moore JP, et al. Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120 AIDS. Res Hum Retroviruses 1998; 14: 191-198.
25. Ghiara JB, Ferguson DC, Satterthwait AC, Dyson HJ, Wilson I A. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. J Mol Biol 1997; 266: 31-39.
26. Ghiara JB, Stura EA, Stanfield RL, Profy AT, Wilson IA. Crystal structure of the principal neutralization site of HIV-1. Science 1994; 264: 82-85.
27. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, Anglister J. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines suggesting a mechanism for coreceptor selectivity Structure. (Camb) 2003; 11: 225-236.
28. Stanfield R, Cabezas E, Satterthwait A, Stura E, Profy A, Wilson I. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. Structure 1999; 7: 131-142.
29. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens antigens and immunogens. Science 1998; 280: 1884-1888.
30. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384: 179-183.
31. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-1148.
32. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 1996; 274: 602-605.
33. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, et al. CD4-dependent antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384: 184-187.
34. Yonezawa A, Hori T, Takaori-Kondo A, Morita R, Uchiyama T. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1. J Virol 2001; 75: 4258-4267.
35. Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002; 76: 8953-8957.
36. Suphaphiphat P, Thitithanyanont A, Paca-Uccaralertkun S, Essex M, Lee TH. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. J Virol 2003; 77: 3832-3837.
37. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine- mediated blockade of infection. Nat Med 1996; 2: 1244-1247.
38. Ross TM, Bieniasz PD, Cullen BR. Role of chemokine receptors in HIV-1 infection and pathogenesis. Adv Virus Res 1999; 52: 233-267.
39. Martin KA, Wyatt R, Farzan M, Choe H, Marcon L, Desjardins E, et al. CD4-independent binding of SIV gp120 to rhesus CCR5. Science 1997; 278: 1470-1473.
40. Farzan M, Choe H, Vaca L, Martin K, Sun Y, Desjardins E, et al. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol 1998; 72: 1160-1164.
41. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, et al. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 1998; 72: 279-285.
42. Labrosse B, Treboute C, Brelot A, Alizon M. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J Virol 2001; 75: 5457-5464.
43. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: another look. Trends Microbiol 1999; 7: 144-149.
44. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74: 1948-1960.
45. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, et al. DC-SIGN a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100: 587-597.
46. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, et al. Identification of DC-SIGN a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100: 575-585.
47. Earl PL, Doms RW, Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1990; 87: 648-652.
48. Lu M, Blacklow SC, Kim PS, A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2: 1075-1082.
49. Chan DC, Fass D, Berger JM, Kim PS Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89: 263-273.
50. Weissenhorn W, Wharton SA, Calder LJ, Earl PL, Moss B, Aliprandis E, et al. The ectodomain of HIV-1 env subunit gp41 forms a soluble alpha-helical rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J 1996; 15: 1507-1514.
51. Zhang CW, Chishti Y, Hussey RE, Reinherz EL. Expression purification and characterization of recombinant HIV gp140 The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer. J Biol Chem 2001; 276: 39577-39585.
52. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70: 777-810.
53. Johnson WE, Sauvron JM, Desrosiers RC. Conserved N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication. J Virol 2001; 75: 11426-11436.
54. Cohen J. HIV gets a taste of its own medicine. Science 1997; 277: 1606.
55. Jiang S, Lin K, Strick N, Neurath AR. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem Biophys Res Commun 1993; 195: 533-538.
56. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91: 9770-9774.
57. Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang HC, Siliciano RF, et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988; 331: 78-81.
58. Deen KC, McDougal JS, Inacker R, Folena-Wasserman G, Arthos J, Rosenberg J, et al. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988; 331: 82-84.
59. Witvrouw M, Desmyter J, De Clercq E. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chem Chemother 1994; 41: 587-593.
60. Ojwang JO, Buckheit RW, Pommier Y, Mazumder A, De Vreese K, Esté JA, et al. T30177 an oligonucleotide stabilized by an intramolecular guanosine octet is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995; 39: 2426-2435.
61. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2 a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11: 533-539.
62. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, et al. Single-dose safety pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV- infected adults. J Infect Dis 2000; 182: 326-329.
63. LaBonte J, Lebbos J, Kirkpatrick P. Enfuvirtide. Nat Rev Drug Discov 2003; 2: 345-346.
64. Wang T, Zhang Z, Wallace OB, Deshpande M, Fang H, Yang Z, et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[23- b] pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003; 46: 4236-4239.
65. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003; 100: 11013-11018.
66. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Friborg J, et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003; 77: 10528-10536.
67. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES MIP-1 alpha and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815.
68. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 1997; 234: 340-348
69. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829-833.
70. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T- cell-line-adapted HIV-1. Nature 1996; 382: 833-835.
71. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, et al. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997; 186: 139-146.
72. Simmons G, Clapham PR, Picard L, Offlord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276: 276-279.
73. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998; 95: 14500-14505.
74. Horuk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S, et al. The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem 1998; 273: 386-391.
75. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham P R, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998; 187: 1215-1224.
76. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997; 186: 1395-1400.
77. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186: 1389-1393.
78. Cabrera C, Gutierrez A, Barretina J, Blanco J, Litovchick A, Lapidot A, et al. Anti-HIV activity of a novel aminoglycoside-arginine conjugate. Antiviral Res 2002; 53: 1-8.
79. Cabrera C, Gutierrez A, Blanco J, Barretina J, Litovchick A, Lapidot A, et al. Anti-human immunodeficiency virus activity of novel aminoglycoside- arginine conjugates at early stages of infection. AIDS Res Hum Retroviruses 2000; 16: 627-634.
80. Daelemans D, Schols D, Witvrouw M, Pannecouque C, Hatse S, van Dooren S, et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 2000; 57: 116-124.
81. Este JA, Cabrera C, De Clercq E, Struyf S, Van Damme J, Bridger G, et al. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol Pharmacol 1999; 55: 67-73.
82. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, et al. AMD3100 a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4: 72-77.
83. Schols D, Este JA, Henson G, De Clercq E. Bicyclams a class of potent anti-HIV agents are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997; 35: 147-156.
84. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186: 1383-1388.
85. De Clercq E. The bicyclam, AMD3100 story. Nat Rev Drug Discov 2003; 2: 581-587.
86. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist KRH-1636 exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003; 17: 17.
87. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96: 5698-5703.
88. Este J A. TAK-779 (Takeda). Curr Opin Investig Drugs 2001; 2: 354-356.
89. Este JA. Virus Entry as a Target for Anti-HIV Intervention. Curr Med Chem 2003; 10: 1617-1632.
90. Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K, et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001; 13: 13.
91. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, et al. Potent Broad-Spectrum Inhibition of Human Immuno-deficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140. J Virol 2001; 75: 579-588.
92. Baroudy BM. In The 1st IAS Conference on HIV Pathogenesis and Treatment: Buenos Aires 2001.
93. Martinez MA, Clotet B, Este JA. RNA interference of HIV replication. Trends Immunol 2002; 23: 559-561.
94. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002; 16: 2385-2390.
95. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93: 681-684.
96. Judice JK, Tom JY, Huang W, Wrin T, Vennari J, Petropoulos CJ, et al. Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. Proc Natl Acad Sci USA 1997; 94: 13426-13430.
97. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20 a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4: 1302-1307.
98. Labrosse B, Labernardiere JL, Dam E, Trouplin V, Skrabal K, Clavel F, et al. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 2003; 77: 1610-1613.
99. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide an HIV-1 Fusion Inhibitor for Drug-Resistant HIV Infection in North and South America. N Engl J Med 2003; 348: 2175-2185.
100. FDA drug approvals list. 2003; http://wwwfdagov/cder/foi/label/2003/0214811blpdf.
101. Este JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, Desmyter J, et al. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol Pharmacol 1997; 52: 98-104.
102. Este JA, Cabrera C, Schols D, Cherepanov P, Gutierrez A, Witvrouw M, et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol 1998; 53: 340-345.
103. Cabrera C, Witvrouw M, Gutierrez A, Clotet B, Kuipers ME, Swart PJ, et al. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. AIDS Res Hum Retroviruses 1999; 15: 1535-1543.
104. Lin PF, Samanta H, Bechtold CM, Deminie CA, Patick AK, Alam M, et al. Characterization of siamycin I a human immunodeficiency virus fusion inhibitor. Antimicrob Agents Chemother 1996; 40: 133-138.
105. de Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, et al. The molecular target of bicyclams potent inhibitors of human immunodeficiency virus replication. J Virol 1996; 70: 689-696.
106. Schols D, Esté JA, Cabrera C, De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998; 72: 4032-4037.
107. Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, Offord RE, et al. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol 2000; 74: 4868-4876.
108. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. HIV-1 escape from a small molecule CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002; 99: 395-400.
109. Riley J, Wojcik L, Xu S, Strizki J. Genotypic and phenotypic analysis of in vitro generated HIV-1 escape isoltes to the CCR5 anatagonist SCH-C 9th Conference on Retroviruses and Opportunistic Infections. Abstract 2002; 397-T.
110. Maeda Y, Foda M, Matsushita S, Harada S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J Virol 2000; 74: 1787-1793.
111. Klasse PJ, Moore JP. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J Virol 1996; 70: 3668-3677.
112. Klasse PJ, McKeating JA. Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization. AIDS Res Hum Retroviruses 1993; 9: 595-604.
113. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990; 87: 6574-6578.
114. Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, Zhang Z, et al. Syndecan captures protects and transmits HIV to T lymphocytes. Immunity 2003; 18: 27-39.
115. Cherepanov P, Esté JA, Rando RF, Ojwang JO, Reekmans G, Steinfeld R, et al. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol Pharmacol 1997; 52: 771-780.
116. De Vreese K, Reymen D, Griffin P, Steinkasserer A, Werner G, Bridger GJ, et al. The bicyclams a new class of potent human immunodeficiency virus inhibitors block viral entry after binding. Antiviral Res 1996; 29: 209-219.
117. Este JA, De Vreese K, Witvrouw M, Schmit JC, Vandamme AM, Anne J, et al. Antiviral activity of the bicyclam derivative JM3100 against drug- resistant strains of human immunodeficiency virus type 1. Antiviral Res 1996; 29: 297-307.
118. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, et al. T134 a small-molecule CXCR4 inhibitor has no cross-drug resistance with AMD3100 a CXCR4 antagonist with a different structure. J Virol 1999; 73: 1719-1723.
119. Kanbara K, Sato S, Tanuma J, Tamamura H, Gotoh K, Yoshimori M, et al. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res Hum Retroviruses 2001; 17: 615-622.
120. Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, et al. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996; 93: 15382-15387.
121. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999; 73: 5577-5585.
122. Rangel HR, Weber J, Chakraborty B, Gutierrez A, Marotta ML, Mirza M, et al. Role of the Human Immunodeficiency Virus Type 1 Envelope Gene in Viral Fitness. J Virol 2003; 77: 9069-9073.
123. Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, et al. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol 2000; 74: 4433-4440.
124. Karlsson GB, Halloran M, Schenten D, Lee J, Racz P, Tenner-Racz K, et al. The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J Exp Med 1998; 188: 1159-1171.
125. LaBonte JA, Patel T, Hofmann W, Sodroski J. Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells. J Virol 2000; 74: 10690-10698.
126. Blanco J, Jacotot E, Cabrera C, Cardona A, Clotet B, De Clercq E, et al. The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. AIDS 1999; 13: 909-917.
127. Blanco J, Barretina J, Henson G, Bridger G, De Clercq E, Clotet B, et al. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface- expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrob Agents Chemother 2000; 44: 51-56.
128. Armand-Ugon M, Quinones-Mateu ME, Gutierez A, Barretina J, Blanco J, Schols D, et al. Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antivir Ther 2003; 8: 1-8.
129. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant ALIVE Study Hemophilia Growth and Development Study (HGDS) Multicenter AIDS Cohort Study (MACS) Multicenter Hemophilia Cohort Study (MHCS) San Francisco City Cohort (SFCC). Science 1998; 279: 389-393.
130. Llano A, Barretina J, Blanco J, Gutierrez A, Clotet B, Este JA. Stromal -cell-derived factor 1 prevents the emergence of the syncytium- inducing phenotype of HIV-1 in vivo. AIDS 2001; 15: 1890-1892.
131. Llano A, Barretina J, Gutierrez A, Blanco J, Cabrera C, Clotet B, et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol 2001; 75: 10319-10325.
132. Llano A, Barretina J, Gutierrez A, Clotet B, Este JA. Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression. J Virol 2003; 77: 4389-4395.
133. Glushakova S, Grivel JC, Fitzgerald W, Sylwester A, Zimmerberg J, Margolis LB. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat Med 1998; 4: 346-349.
134. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-1181.
135. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73: 3544-3550.
136. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003; 100: 10598-10602.
137. Rimsky LT, Shugars DC, Matthews TJ. Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides. J Virol 1998; 72: 986-993.
138. Greenberg M, McDanal C, Sanfield-Oakley S, Jin L, Tremblay C, Sista P, et al. In 8th Conference on Retroviruses and Opportunistic Infections: Chicago USA, 2001.
139. Miralles G, DeMasi R, Sista P, Melby T, Duff F, Matthews T. Baseline genotype and prior antiretroviral history do not affect virological response to T-1249. Antivir Therapy 2001; 6: 3-4.
140. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20 a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4: 1302-1307.
141. Armand-Ugon M, Gutierrez A, Clotet B, Este JA. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res 2003; 59: 137-142.
142. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virot 2000; 74: 8358-8367.
143. Doms RW. Virus attachment receptor engagement and membrane fusion Keystone Symposium on HIV Pathogenesis 2002; Abstract 014.
144. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000; 25: 99-102.
145. Pleskoff O, Sol N, Marrakchi H, Serlin M, Seman M, Alizon M. Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry. J Virol 1996; 70: 8247-8251.
146. De Vreese K, Van Nerum I, Vermeire K, Anne J, De Clercq E. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob Agents Chemother 1997; 41: 2616-2620.
147. Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, et al. Determination of coreceptor usage of human immuno-deficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001; 75: 251-259.
148. Win T, Huang W, Yap J, Fransen S, Paxinos E, Parkin N, et al. Evaluating HIV-1 co-receptor usage and inhibitors of virus entry using recombinant virus assays. Antiviral Therapy 2001; 6: 3.
149. Blanco J, Barretina J, Cabrera C, Gutierrez A, Clotet B, Este JA. CD4(+) and CD8(+) t cell death during human immunodeficiency virus infection in vitro. Virology 2001;285: 356-365.
150. Fikkert V, Cherepanov P, Van Laethem K, Hantson A, Van Remoortel B, Pannecouque C, et al. env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents Chemother 2002, 46: 3954-3962.
151. Gulick RM. New antiretroviral drugs. Clin Microbiol Infect 2003; 9: 186-193.
152. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials March 2003 Methods Find. Exp Clin Pharmacol 2003; 25: 145-168.
153. Madani N, Perdigoto AL, Srinivasan K, Cox JM, Chruma JJ, LaLonde J, et al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155 J Virol 2004; 78: 3742-3752.
154. Holland AU, Munk C, Lucero GR, Nguyen LD, Landau NR. Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 2004; 319: 343-352.
155. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Design 2002; 8(8): 615-57.
156. Nair V. Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents. Curr Pharm Design 2003; 9(31): 2553-65.
157. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, et al. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches. Curr Pharm Design 2002; 8(8): 595-614.